CRA-026440

CRA-026440 is a potent, broad-spectrum small molecule inhibitor of histone deacetylases (HDACs), specifically targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10. Developed as an antineoplastic agent, it belongs to the hydroxamic acid class of HDAC inhibitors. Its mechanism involves the accumulation of acetylated histones and tubulin, which leads to the inhibition of tumor cell proliferation and the induction of apoptosis. Preclinical evaluations have demonstrated significant antitumor and antiangiogenic activities in various human tumor models, including colorectal cancer and leukemia. The compound is primarily used as a research tool to study the effects of broad-spectrum HDAC inhibition on tumor growth and angiogenesis.